Warning! GuruFocus detected
5 Severe warning signs
with OND.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Oncopeptides AB
ISIN : SE0009414576
Compare
Compare
Traded in other countries / regions
ONCO.SwedenOND.Germany0RN4.UKONPPF.USA IPO Date
2020-07-21Description
Oncopeptides AB is a biotech company focused on the research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Conjugate (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It has focused on the development of the product candidate Melflufen (Pepaxti), a peptide-conjugated alkylator, belonging to a new class of drugs called Peptidase Enhanced Compounds. Melflufen is intended as an effective treatment for hematological cancers and in particular multiple myeloma.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.47 | |||||
| Equity-to-Asset | 0.22 | |||||
| Debt-to-Equity | 2.25 | |||||
| Debt-to-EBITDA | -0.43 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -1.76 | |||||
| Beneish M-Score | 3.54 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -44.6 | |||||
| 3-Year EBITDA Growth Rate | 49.6 | |||||
| 3-Year EPS without NRI Growth Rate | 49.8 | |||||
| 3-Year FCF Growth Rate | 52.2 | |||||
| 3-Year Book Growth Rate | -49.5 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 122.01 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 82.85 | |||||
| 9-Day RSI | 71.65 | |||||
| 14-Day RSI | 64 | |||||
| 3-1 Month Momentum % | 1.19 | |||||
| 6-1 Month Momentum % | -24.97 | |||||
| 12-1 Month Momentum % | -62.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.23 | |||||
| Quick Ratio | 4.14 | |||||
| Cash Ratio | 3.48 | |||||
| Days Inventory | 577.7 | |||||
| Days Sales Outstanding | 366.26 | |||||
| Days Payable | 1946.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26 | |||||
| Shareholder Yield % | -0.7 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 91.58 | |||||
| Operating Margin % | -895.79 | |||||
| Net Margin % | -899.29 | |||||
| FCF Margin % | -822.87 | |||||
| ROE % | -329.98 | |||||
| ROA % | -97.84 | |||||
| ROIC % | -337.35 | |||||
| 3-Year ROIIC % | -767.72 | |||||
| ROC (Joel Greenblatt) % | -936.65 | |||||
| ROCE % | -126.32 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.26 | |||||
| PB Ratio | 6.48 | |||||
| Price-to-Tangible-Book | 7.72 | |||||
| EV-to-EBIT | -1.04 | |||||
| EV-to-EBITDA | -1.04 | |||||
| EV-to-Revenue | 9.33 | |||||
| EV-to-FCF | -1.13 | |||||
| Price-to-GF-Value | 0.7 | |||||
| Price-to-Net-Current-Asset-Value | 15.44 | |||||
| Earnings Yield (Greenblatt) % | -96.15 | |||||
| FCF Yield % | -74.03 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oncopeptides AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2.781 | ||
| EPS (TTM) (€) | -0.15 | ||
| Beta | 0.52 | ||
| 3-Year Sharpe Ratio | 0.04 | ||
| 3-Year Sortino Ratio | 0.07 | ||
| Volatility % | 52.79 | ||
| 14-Day RSI | 64 | ||
| 14-Day ATR (€) | 0.004996 | ||
| 20-Day SMA (€) | 0.13801 | ||
| 12-1 Month Momentum % | -62.15 | ||
| 52-Week Range (€) | 0.1108 - 0.397 | ||
| Shares Outstanding (Mil) | 211.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oncopeptides AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oncopeptides AB Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Oncopeptides AB Frequently Asked Questions
What is Oncopeptides AB(STU:OND)'s stock price today?
The current price of STU:OND is €0.15. The 52 week high of STU:OND is €0.40 and 52 week low is €0.11.
When is next earnings date of Oncopeptides AB(STU:OND)?
The next earnings date of Oncopeptides AB(STU:OND) is 2025-05-08.
Does Oncopeptides AB(STU:OND) pay dividends? If so, how much?
Oncopeptides AB(STU:OND) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers